Skip to main content
Fachgebiete
Automobil + Motoren Bauwesen + Immobilien Business IT + Informatik Elektrotechnik + Elektronik Energie + Nachhaltigkeit Finance + Banking Management + Führung Marketing + Vertrieb Maschinenbau + Werkstoffe Versicherung + Risiko
DE
EN
Themenseiten
Organisationspsychologie Projektmanagement Marketing Smart Manufacturing
Bücher
Zeitschriften
Weitere Formate
Podcasts Webinare Technik Webinare Wirtschaft Kongresse Veranstaltungskalender Awards
Jetzt Einzelzugang starten
Zugang für Unternehmen
Referenzkunden
ATZ-Fachkongress

Chassis.tech plus 2024


4 Kongresse in einer Veranstaltung

Treffen Sie in München die Fachleute von Chassis, Lenkung, Bremsen sowie Reifen/Räder.
Erweiterte Suche
Anmelden
nach oben
Journal of Materials Science
Erschienen in: Journal of Materials Science 16/2020

28.02.2020 | Materials for life sciences

Branched worm-like nanoparticles featured with programmed drug release for synergistic castration-resistant prostate cancer therapy

verfasst von: Hang Hu, Chong Wang, Rong Zhang, Chen Xiao, Chao Lai, Zifu Li, Defeng Xu

Erschienen in: Journal of Materials Science | Ausgabe 16/2020

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Co-delivery systems with programmed release of combined drugs are of great value for combination cancer therapy. However, design of such co-delivery systems for potent synergistic cancer therapy is still a great challenge. In the present work, dimethylcurcumin (DMC) and docetaxel (DTX) co-loaded branched worm-like nanoparticles (NPs) with programmed release of DMC and DTX were developed for potent synergistic castration-resistant prostate cancer (CRPC) therapy. (2-Hydroxypropyl)-β-cyclodextrin-retinoic acid (HP-β-CD-RA) conjugates with different molar ratios of RA to HP-β-CD were synthesized and used for the preparation of DMC and DTX co-loaded NPs. The as-prepared DMC and DTX co-loaded NPs (Dh 170–190 nm) have branched worm-like morphologies, and DMC/DTX@HP-β-CD-RA3.0 NPs show the highest drug loading content and encapsulation efficiency. DMC/DTX@HP-β-CD-RA3.0 NPs exhibit programmed drug release patterns with DTX released much faster than DMC, which could be ascribed to the difference between DMC and DTX in the interaction with HP-β-CD-RA3.0 as analyzed by molecular simulation, phase solubility method, and fluorescence spectra. DMC/DTX@HP-β-CD-RA3.0 NPs exhibit enhanced cellular uptake as compared to DMC/DTX. Mechanism dissection reveals that the cellular uptake of DMC/DTX@HP-β-CD-RA3.0 NPs is energy-dependent in which macropinocytosis and clathrin- and caveolae-independent endocytosis pathways are involved. Benefited from their enhanced cellular uptake and programmed drug release, DMC/DTX@HP-β-CD-RA3.0 NPs exhibit significantly enhanced antitumor effect as compared to DMC/DTX. Such mechanisms for potent synergistic antitumor effect, by enhancing cellular uptake of DMC and DTX together with programmed drug release, may provide new therapeutic options for CRPC.
Vorheriger Artikel Visible-light-responsive folate-conjugated titania and alumina nanotubes for photodynamic therapy applications
Nächster Artikel Semiconducting antiferromagnet of Cr2FeSi and CrMn2Si Heusler compound films

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Jetzt informieren
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424
2.
Cioni B, Zwart W, Bergman AM (2018) Androgen receptor moonlighting in the prostate cancer microenvironment. Endocr Relat Cancer 25:R331–R349
3.
Yap TA, Smith AD, Ferraldeschi R, Al-Lazikani B, Workman P, de Bono JS (2016) Drug discovery in advanced prostate cancer: translating biology into therapy. Nat Rev Drug Discov 15:699–718
4.
Wadosky KM, Koochekpour S (2016) Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget 7:64447–64470
5.
Chen X, Li Q, Liu X et al (2016) Defining a population of stem-like human prostate cancer cells that can generate and propagate castration-resistant prostate cancer. Clin Cancer Res 22:4505–4516
6.
De Maeseneer DJ, Van Praet C, Lumen N, Rottey S (2015) Battling resistance mechanisms in antihormonal prostate cancer treatment: novel agents and combinations. Urol Oncol Semin Orig Investig 33:310–321
7.
Nevedomskaya E, Baumgart SJ, Haendler B (2018) Recent advances in prostate cancer treatment and drug discovery. Int J Mol Sci 19:1359
8.
Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M (1994) Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 50:267–273
9.
Attard G, Belldegrun AS, De Bono JS (2005) Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 96:1241–1246
10.
Scher HI, Beer TM, Higano CS et al (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375:1437–1446
11.
Ciccarese C, Nobili E, Grilli D, Casolari L, Rihawi K, Gelsomino F, Tortora G, Massari F (2016) The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer. Expert Rev Anticancer Ther 16:681–696
12.
Scott LJ (2007) Abiraterone acetate: a review in metastatic castration-resistant prostrate cancer. Drugs 77:1565–1576
13.
Haapala K, Kuukasjärvi T, Hyytinen E, Rantala I, Helin HJ, Koivisto PA (2007) Androgen receptor amplification is associated with increased cell proliferation in prostate cancer. Hum Pathol 38:474–478
14.
Edwards J, Krishna NS, Grigor KM, Bartlett JMS (2003) Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89:552–556
15.
Koivisto P, Kononen J, Palmberg C et al (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57:314–319
16.
Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA, Visakorpi T (2009) Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 69:8141–8149
17.
Hu R, Dunn TA, Wei S et al (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69:16–22
18.
Fenner A (2012) Unravelling AR splice variant signalling in CPRC. Nat Rev Urol 9:410
19.
Nakazawa M, Antonarakis ES, Luo J (2014) Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer 5:265–273
20.
Guo Z, Yang X, Sun F et al (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69:2305–2313
21.
Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER (1992) Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci 89:6319–6323
22.
Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S (1994) Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54:2861–2864
23.
Wu MH, Ma WL, Hsu CL et al (2010) Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med 2:32–35
24.
Yang Z, Chang YJ, Yu IC et al (2007) ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med 13:348–353
25.
Lai KP, Huang CK, Chang YJ et al (2013) New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol 182:460–473
26.
Miyamoto H, Yang Z, Chen YT et al (2007) Promotion of bladder cancer development and progression by androgen receptor signals. JNCI J Natl Cancer Inst 99:558–568
27.
Yamashita S, Lai KP, Chuang KL et al (2012) ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia 14:74–83
28.
Wang R, Lin W, Lin C, Li L, Sun Y, Chang C (2016) ASC-J9® suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L. Cancer Lett 379:154–160
29.
Lin TH, Izumi K, Lee SO, Lin WJ, Yeh S, Chang C (2013) Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis 4:e764
30.
Lin W, Luo J, Sun Y, Lin C, Li G, Niu Y, Chang C (2018) ASC-J9 ® suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3. Cancer Lett 425:21–30
31.
Lin TH, Lee SO, Niu Y et al (2013) Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/enzalutamide versus anti-androgen receptor ASC-J9® lead to promotion versus suppression of prostate cancer metastasis. J Biol Chem 288:19359–19369
32.
Michael A, Syrigos K, Pandha H (2008) Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer Prostatic Dis 12:13–16
33.
Tewari AK, George DJ (2013) Novel chemotherapies in development for management of castration-resistant prostate cancer. Curr Opin Urol 23:220–229
34.
Yuan B, Liu Y, Yu X et al (2018) FOXM1 contributes to taxane resistance by regulating UHRF1-controlled cancer cell stemness. Cell Death Dis 9:562
35.
Galletti E, Magnani M, Renzulli ML, Botta M (2007) Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem 2:920–942
36.
Qian DZ, Rademacher BLS, Pittsenbarger J et al (2010) CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate 70:433–442
37.
O’Neill AJ, Prencipe M, Dowling C et al (2011) Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer 10:126
38.
Luo J, Tian J, Chou F et al (2019) Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression. Cancer Lett 444:35–44
39.
Kang L, Gao Z, Huang W, Jin M, Wang Q (2015) Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment. Acta Pharm Sin B 5:169–175
40.
Upponi JR, Jerajani K, Nagesha DK, Kulkarni P, Sridhar S, Ferris C, Torchilin VP (2018) Polymeric micelles: theranostic co-delivery system for poorly water-soluble drugs and contrast agents. Biomaterials 170:26–36
41.
Hu H, Xiao C, Wu H et al (2017) Nanocolloidosomes with selective drug release for active tumor-targeted imaging-guided photothermal/chemo combination therapy. ACS Appl Mater Interfaces 9:42225–42238
42.
Geng Y, Discher DE (2006) Visualization of degradable worm micelle breakdown in relation to drug release. Polymer 47:2519–2525
43.
Devarajan PV, Jindal AB, Patil RR, Mulla F, Gaikwad RV, Samad A (2010) Particle shape: a new design parameter for passive targeting in splenotropic drug delivery. J Pharm Sci 99:2576–2581
44.
Park JH, von Maltzahn G, Zhang L et al (2009) Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small 5:694–700
45.
Decuzzi P, Ferrari M (2006) The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials 27:5307–5314
46.
Cao S, Shao J, Xia Y et al (2019) Molecular programming of biodegradable nanoworms via ionically induced morphology switch toward asymmetric therapeutic carriers. Small 15:e1901849
47.
48.
Gould S, Scott RC (2005) 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): a toxicology review. Food Chem Toxicol 43:1451–1459
49.
Schenk T, Stengel S, Zelent A (2014) Unlocking the potential of retinoic acid in anticancer therapy. Br J Cancer 111:2039–2045
50.
Bartolini G, Ammar K, Mantovani B, Scanabissi F, Ferreri AM, Rocchi P, Orlandi M (2004) Retinoids and cancer: antitumor effect of ATRA and of a new derivative of retinoic acid, IIF, on colon carcinoma cell lines CaCo-2 and HT-29. Anticancer Res 24:1779–1783
51.
Liu H, Zang C, Fenner MH, Possinger K, Elstner E (2003) PPARγ ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat 79:63–74
52.
Arce F, Gätjens-Boniche O, Vargas E, Valverde B, Díaz C (2005) Apoptotic events induced by naturally occurring retinoids ATRA and 13-cis retinoic acid on human hepatoma cell lines Hep3B and HepG2. Cancer Lett 229:271–281
53.
Clausen TM, Vinson PK, Minter JR, Davis HT, Talmon Y, Miller WG (1992) Viscoelastic micellar solutions: microscopy and rheology. J Phys Chem 96:474–484
54.
Lin Z (1996) Branched worm-like micelles and their networks. Langmuir 12:1729–1737
55.
Shikata T, Hirata H, Kotaka T (1988) Micelle formation of detergent molecules in aqueous media. 2. Role of free salicylate ions on viscoelastic properties of aqueous cetyltrimethylammonium bromide-sodium salicylate solutions. Langmuir 4:354–359
56.
Mitchell DJ, Ninham BW (1981) Micelles, vesicles and microemulsions. J Chem Soc Faraday Trans 2 Mol Chem Phys 77:601–629
57.
Israelachvili JN, Mitchell DJ, Ninham BW (1976) Theory of self-assembly of hydrocarbon amphiphiles into micelles and bilayers. J Chem Soc Faraday Trans 2 Mol Chem Phys 72:1525–1568
58.
Szejtli J (1998) Introduction and general overview of cyclodextrin chemistry. Chem Rev 98:1743–1754
59.
Lu J, Chuan X, Zhang H, Dai W, Wang X, Wang X, Zhang Q (2014) Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo. Int J Pharm 471:525–535
60.
Yang J, Gong X, Wang G (2015) Compatibility and mechanical properties of BAMO–AMMO/DIANP composites: a molecular dynamics simulation. Comput Mater Sci 102:1–6
61.
Jarho P, Urtti A, Pate DW, Suhonen P, Järvinen T (1996) Increase in aqueous solubility, stability and in vitro corneal permeability of anandamide by hydroxypropyl-β-cyclodextrin. Int J Pharm 137:209–216
62.
Hu H, Wan J, Huang X, Tang Y, Xiao C, Xu H, Yang X, Li Z (2018) iRGD-decorated reduction-responsive nanoclusters for targeted drug delivery. Nanoscale 10:10514–10527
63.
Song Q, Wang X, Wang Y et al (2015) Reduction responsive self-assembled nanoparticles based on disulfide-linked drug-drug conjugate with high drug loading and antitumor efficacy. Mol Pharm 137:209–216
64.
Chou TC (2018) The combination index (CI < 1) as the definition of synergism and of synergy claims. Synergy 7:49–50
Metadaten
Titel
Branched worm-like nanoparticles featured with programmed drug release for synergistic castration-resistant prostate cancer therapy
verfasst von
Hang Hu
Chong Wang
Rong Zhang
Chen Xiao
Chao Lai
Zifu Li
Defeng Xu
Publikationsdatum
28.02.2020
Verlag
Springer US
Erschienen in
Journal of Materials Science / Ausgabe 16/2020
Print ISSN: 0022-2461
Elektronische ISSN: 1573-4803
DOI
https://doi.org/10.1007/s10853-020-04495-9

Weitere Artikel der Ausgabe 16/2020

Journal of Materials Science 16/2020 Zur Ausgabe

Chemical routes to materials

Preparation of molecularly imprinted polymers for sensing of 2,4-dichlorophenoxyacetic acid residues in environmental water and mixed juice

Ceramics

Interrelation of electrocaloric and concomitant effects in lead magnesium niobate based ceramics

Polymers & biopolymers

Determination of the X-ray attenuation coefficient of bismuth oxychloride nanoplates in polydimethylsiloxane

Chemical routes to materials

Molecularly imprinted nanoparticles (nanoMIPs): an efficient new adsorbent for removal of arsenic from water

Polymers & biopolymers

Hydroxypropyl-modified and organosolv lignin/bio-based polyamide blend filaments as carbon fibre precursors’

Composites & nanocomposites

Structure and evolution of multiphase composites for 3D printing

Premium Partner

    Marktübersichten

    Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen. 

    Zur Marktübersicht
    Bildnachweise